Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Related Articles by Review for PubMed (Select 23634292)

1.

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?

Cha E, Small EJ.

Cancer Med. 2013 Apr;2(2):243-52. doi: 10.1002/cam4.64. Epub 2013 Feb 24. Review.

2.

The evolving role of immunotherapy in prostate cancer.

Gerritsen WR.

Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259. Review.

3.

Ipilimumab in prostate cancer.

Singh N, Madan RA, Gulley JL.

Expert Opin Biol Ther. 2013 Feb;13(2):303-13. doi: 10.1517/14712598.2012.754421. Epub 2012 Dec 25. Review.

PMID:
23265575
4.

Role of immunotherapy in castration-resistant prostate cancer (CRPC).

Suárez C, Morales-Barrera R, Ramos V, Núñez I, Valverde C, Planas J, Morote J, Maldonado X, Carles J.

BJU Int. 2014 Mar;113(3):367-75. doi: 10.1111/bju.12110. Epub 2013 Apr 12. Review.

PMID:
23650874
5.

Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.

Spigel DR, Socinski MA.

J Thorac Oncol. 2013 May;8(5):587-98. doi: 10.1097/JTO.0b013e318286cf88. Review.

PMID:
23546044
6.

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Zielinski C, Knapp S, Mascaux C, Hirsch F.

Ann Oncol. 2013 May;24(5):1170-9. doi: 10.1093/annonc/mds647. Epub 2013 Feb 7. Review.

7.

Beyond sipuleucel-T: immune approaches to treating prostate cancer.

Cheng ML, Fong L.

Curr Treat Options Oncol. 2014 Mar;15(1):115-26. doi: 10.1007/s11864-013-0267-z. Review.

PMID:
24402184
8.

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

Graziani G, Tentori L, Navarra P.

Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21930211
9.

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso JF, Jure-Kunkel MN.

Cancer Immun. 2013;13:5. Epub 2013 Jan 22. Review.

10.

Current status of immunological approaches for the treatment of prostate cancer.

Drake CG, Antonarakis ES.

Curr Opin Urol. 2012 May;22(3):197-202. doi: 10.1097/MOU.0b013e3283519ad5. Review.

11.

Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.

Lens M, Testori A, Ferucci PF.

Curr Top Med Chem. 2012;12(1):61-6. Review.

PMID:
22196270
12.

Update on the role of ipilimumab in melanoma and first data on new combination therapies.

Maio M, Di Giacomo AM, Robert C, Eggermont AM.

Curr Opin Oncol. 2013 Mar;25(2):166-72. doi: 10.1097/CCO.0b013e32835dae4f. Review.

PMID:
23299197
13.

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Ott PA, Hodi FS, Robert C.

Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143. Review.

14.

Current role of immunotherapy for the treatment of prostate cancer.

Porfyris O, Kalomoiris P.

J BUON. 2013 Oct-Dec;18(4):809-17. Review.

PMID:
24344002
15.

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.

Singh BH, Gulley JL.

Asian J Androl. 2014 May-Jun;16(3):364-71. doi: 10.4103/1008-682X.122585. Review.

16.

Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Callahan MK, Postow MA, Wolchok JD.

Clin Dermatol. 2013 Mar-Apr;31(2):191-9. doi: 10.1016/j.clindermatol.2012.08.006. Review.

17.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R.

Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Review.

PMID:
21074069
18.

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

Weber J.

Oncologist. 2008;13 Suppl 4:16-25. doi: 10.1634/theoncologist.13-S4-16. Review.

19.

Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma.

Tosti G, Cocorocchio E, Pennacchioli E.

Clin Cosmet Investig Dermatol. 2013 Oct 17;6:245-56. doi: 10.2147/CCID.S24246. Review.

20.

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.

Blank CU.

Curr Opin Oncol. 2014 Mar;26(2):204-14. doi: 10.1097/CCO.0000000000000054. Review.

PMID:
24424272
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk